Physicians use PCI to open blood vessels to the heart that are narrowed or blocked ... “In addition to offering next-generation stents, Abbott is helping physicians by providing technologies ...

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease located below the knee, following the implant’s approval by the FDA ...

WASHINGTON, D.C.—A large-scale, randomized trial of the orbital atherectomy system Abbott picked ... within the heart’s coronary arteries ahead of the implantation of a stent.

15 million Americans have coronary artery disease (CAD). Every year, approximately 600,000 patients require a stent implant when there is plaque buildup in their arteries, which reduces proper blood ...

In the trial, sponsored by US stent manufacturer Abbott, half the patients were given stents, the other half had open heart surgery. Not all the patients were recruited at the same time.

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a late ...

Abbott Laboratories, the world's largest maker of heart stents and adult nutritional beverages, is doubling down on the crowded $6.2 billion U.S. snack market with a line of six bars that it hopes ...

Abbott's Ultreon software is billed ... Francis Hospital and Heart Center in New York. It allows stents to be placed faster and with more precision, helping doctors provide the best care for ...